The potential of more affordable diabetic care comes in the wake of Swiss major Novartis-owned Vildagliptin losing patent on Monday — a development closely watched for months. Dozens of companies have readied plans to get a slice of the action in the growing Rs 14,000-crore diabetes therapy market, with the number of players expected to cross 50 soon.
from Times of India https://ift.tt/2LEI6Bu
Monday, 9 December 2019
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment